?? ?Product Overview?
?Dienogestrel? (CAS: 65928-58-7) is a synthetic progesterone receptor agonist widely used for treating endometriosis, hormonal contraception, and gynecological disorders. With the molecular formula ?C??H??NO?? and molecular weight ?311.42?, it exhibits strong endometrial activity and reduces estrogen-dependent pathological growth. This high-purity compound is critical in ?pharmaceutical formulations?, ?clinical therapy?, and ?reproductive health research?, offering precise hormonal regulation.

? ?Key Advantages?
?? ?High Purity?: ≥99% HPLC-certified quality, ensuring pharmaceutical-grade performance.
?? ?Stability?: Stable under ambient storage (2–25°C) with a 2-year shelf life.
?? ?Clinical Efficacy?: Reduces endometriosis-associated pain by 70% in clinical trials.
?? ?Structural Confirmation?: Verified by NMR, MS, and chromatographic analysis.

?? ?Applications?
? ?Pharmaceuticals?: Key ingredient in hormonal contraceptives and endometriosis therapies (e.g., Visanne?).
? ?Clinical Use?: Approved for endometriosis management and uterine bleeding control.
? ?Research?: Studied for progesterone receptor modulation and anti-inflammatory effects.

?? ?Quality Certifications?
? Complies with ?USP/EP standards? for impurities (<0.1%), residual solvents, and heavy metals.
? Batch-specific COA includes purity (≥99%), moisture (≤0.5%), and single impurity (<0.1%).
? Rigorous testing via HPLC (>98% purity), NMR, and mass spectrometry.

?? ?Market Trends?
The global progesterone drugs market is projected to grow at ?6.8% CAGR (2025–2030)?, driven by rising endometriosis prevalence and demand for non-invasive hormonal therapies. Dienogestrel holds a dominant position in gynecological APIs, with expanding applications in Europe and Asia-Pacific.